ASH 2022 Abstracts

953 FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma MaurerCerhanyesyes
2860 Prediction of Early Disease Progression at 24 Months (POD24) Using Pre-Treatment Biopsies from Patients with Follicular Lymphoma (FL) Treated with Immunochemotherapy (IC) WrightRimszayesno
724 Integrative Genomics Identifies a High-Risk Metabolic and TME Depleted Signature That Predicts Early Clinical Failure in DLBCL WenzlNovakyesno
1541 Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma StokesGandhiyesno
2957 Outcomes and Prognostic Factors of Transformed Follicular Lymphoma: An Analysis from the LEO Consortium DayLinkyesyes
2889 Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma TawfiqYucaiCReWEno
2900 Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting GileYucaiCReWEno
1591 Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study RuanFeldmanyesyes
4156 Molecular Landscape of Primary Refractory DLBCL BockNovakyesno
545 A Genome-Wide Association Study (GWAS) of Event-Free Survival (EFS) in Follicular Lymphoma Patients Treated with Front-Line Immunochemotherapy: A Lysa, Iowa/Mayo MER, and FIL Study HerveCerhanyesno
2966 Dose Intensity and Reasons for Dose Alterations in Patients Excluded from Frontline Diffuse Large B-Cell Lymphoma Clinical Trials Based on Eligibility Criteria: A Mayo Clinic Cohort Study KhuranaMaureryesno
850 Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis KhuranaNowakowskinoyes
4207 Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement in Marginal Zone Lymphoma (MZL): An Analysis from LEO MZL Working Group AlduruccioLossosnoyes
798 Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Era DesaiCerhanyesno
793 Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma LuanMartinyesyes
313 Development and Validation of the advanced-Stage Hodgkin Lymphoma (HL) International Prognostication Index (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium RoddayParsonsyesno
Hypomagnesemia in Untreated Diffuse Large B-cell Lymphoma GileWitzigyesno